Comparative Pharmacology
Head-to-head clinical analysis: PRALATREXATE versus SCEMBLIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRALATREXATE versus SCEMBLIX.
PRALATREXATE vs SCEMBLIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folate analogue metabolic inhibitor that competitively inhibits dihydrofolate reductase (DHFR), disrupting DNA synthesis and cell proliferation.
Selective inhibitor of BCR-ABL1 tyrosine kinase, targeting the myristoyl pocket (STAMP) to induce inactive conformation of BCR-ABL1, including T315I mutant.
30 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
200 mg orally once daily with a meal.
None Documented
None Documented
Terminal elimination half-life is approximately 12–19 hours in patients with normal renal function, supporting a weekly dosing interval.
Clinical Note
moderatePralatrexate + Digoxin
"Pralatrexate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePralatrexate + Digitoxin
"Pralatrexate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePralatrexate + Deslanoside
"Pralatrexate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePralatrexate + Acetyldigitoxin
"Pralatrexate may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life approximately 21–23 hours (range 10–35 h). Supports once-daily dosing.
Renal excretion accounts for approximately 70-80% of the administered dose as unchanged drug; biliary/fecal elimination is minimal (<10%).
Primarily fecal (77%) with minor renal excretion (11%). Biliary excretion contributes to fecal elimination; <1% excreted unchanged in urine.
Category C
Category C
Antineoplastic
Tyrosine Kinase Inhibitor, Antineoplastic